Citation: | TANG Jue, YAO Zhirong. Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 473-479. DOI: 10.12290/xhyxzz.2021-0747 |
[1] |
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis[J]. Nat Rev Dis Primers, 2018, 4: 1.
|
[2] |
Shaw TE, Currie GP, Koudelka CW, et al. Eczema pre-valence in the United States: data from the 2003 National Survey of Children's Health[J]. J Invest Dermatol, 2011, 131: 67-73. DOI: 10.1038/jid.2010.251
|
[3] |
Albrecht M, Dittrich AM. Expression and function of histamine and its receptors in atopic dermatitis[J]. Mol Cell Pediatr, 2015, 2: 16. DOI: 10.1186/s40348-015-0027-1
|
[4] |
Bataille A, Leschiera R, L'Hérondelle K, et al. In Vitro Differentiation of Human Skin-Derived Cells into Functional Sensory Neurons-Like[J]. Cells, 2020, 9: 1000. DOI: 10.3390/cells9041000
|
[5] |
Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1[J]. J Allergy Clin Immunol, 2014, 133: 448-460. DOI: 10.1016/j.jaci.2013.10.048
|
[6] |
Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond[J]. Br J Dermatol, 2019, 180: 464-474. DOI: 10.1111/bjd.16934
|
[7] |
Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch[J]. Cell, 2017, 171: 217-228. e13. DOI: 10.1016/j.cell.2017.08.006
|
[8] |
Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013, 155: 285-295. DOI: 10.1016/j.cell.2013.08.057
|
[9] |
Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview[J]. Exp Dermatol, 2002, 11: 12-24. DOI: 10.1034/j.1600-0625.2002.110102.x
|
[10] |
Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. DOI: 10.1016/j.cell.2020.12.033
|
[11] |
Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade[J]. J Allergy Clin Immunol, 1997, 99: 640-647. DOI: 10.1016/S0091-6749(97)70026-5
|
[12] |
Tsagareli MG, Nozadze I, Tsiklauri N, et al. Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators: Respective Involvement of TRPV1 and TRPA1[J]. Neuroscience, 2020, 449: 35-45. DOI: 10.1016/j.neuroscience.2020.09.048
|
[13] |
McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519: 237-241. DOI: 10.1038/nature14022
|
[14] |
Chandran V, Coppola G, Nawabi H, et al. A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program[J]. Neuron, 2016, 89: 956-970. DOI: 10.1016/j.neuron.2016.01.034
|
[15] |
Zhang H, Guo Y, Wang W, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis[J]. Allergy, 2011, 66: 420-427. DOI: 10.1111/j.1398-9995.2010.02493.x
|
[16] |
Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis[J]. Allergy, 2015, 70: 887-896. DOI: 10.1111/all.12632
|
[17] |
Mack MR, Kim BS. The Itch-Scratch Cycle: A Neuroim-mune Perspective[J]. Trends Immunol, 2018, 39: 980-991. DOI: 10.1016/j.it.2018.10.001
|
[18] |
Uche LE, Gooris GS, Bouwstra JA, et al. Barrier Capability of Skin Lipid Models: Effect of Ceramides and Free Fatty Acid Composition[J]. Langmuir, 2019, 35: 15376-15388. DOI: 10.1021/acs.langmuir.9b03029
|
[19] |
Imai Y, Yasuda K, Nagai M, et al. IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils[J]. J Invest Dermatol, 2019, 139: 2185-2194. e3. DOI: 10.1016/j.jid.2019.04.016
|
[20] |
Smith L, Gatault S, Casals-Diaz L, et al. House dust mite-treated PAR2 over-expressor mouse: A novel model of atopic dermatitis[J]. Exp Dermatol, 2019, 28: 1298-1308. DOI: 10.1111/exd.14030
|
[21] |
Skabytska Y, Kaesler S, Volz T, et al. The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments[J]. Semin Immunopathol, 2016, 38: 29-43. DOI: 10.1007/s00281-015-0544-y
|
[22] |
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progres-sive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis[J]. J Allergy Clin Immunol, 2012, 130: 1344-1354. DOI: 10.1016/j.jaci.2012.07.012
|
[23] |
Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs[J]. Allergy, 2020, 75: 1582-1605. DOI: 10.1111/all.14318
|
[24] |
Tsoi LC, Rodriguez E, Stölzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses[J]. J Allergy Clin Immunol, 2020, 145: 1406-1415. DOI: 10.1016/j.jaci.2019.11.047
|
[25] |
Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms[J]. Proc Natl Acad Sci USA, 2009, 106: 11330-11335. DOI: 10.1073/pnas.0905605106
|
[26] |
Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. DOI: 10.1016/j.cell.2020.12.033
|
[27] |
Song S, Lee K, Lee YM, et al. Acute health effects of urban fine and ultrafine particles on children with atopic dermatitis[J]. Environ Res, 2011, 111: 394-399. DOI: 10.1016/j.envres.2010.10.010
|
[28] |
中国医师协会皮肤科医师分会过敏性疾病专业委员会, 中华医学会皮肤性病学分会特应性皮炎研究中心, 中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识[J]. 中华皮肤科杂志, 2021, 54: 391-396.
|
[29] |
Oyoshi MK, Larson RP, Ziegler SF, et al. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression[J]. J Allergy Clin Immunol, 2010, 126: 976-984. e9845. DOI: 10.1016/j.jaci.2010.08.041
|
[30] |
Howell MD, Novak N, Bieber T, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis[J]. J Invest Dermatol, 2005, 125: 738-745. DOI: 10.1111/j.0022-202X.2005.23776.x
|
[31] |
Hon KL, Tsang YC, Pong NH, et al. Patient acceptabi-lity, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema[J]. Hong Kong Med J, 2015, 21: 417-425.
|
[32] |
Seo SR, Lee SG, Lee HJ, et al. Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis[J]. Acta Derm Venereol, 2017, 97: 957-958. DOI: 10.2340/00015555-2699
|
[33] |
Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines[J]. J Clin Psychopharmacol, 2002, 22: 511-515. DOI: 10.1097/00004714-200210000-00012
|
[34] |
Zhang X, Wu Z, Hayashi Y, et al. Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state[J]. J Neurosci, 2014, 34: 3013-3022. DOI: 10.1523/JNEUROSCI.3681-13.2014
|
[35] |
Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC-14028 cream-a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase Ⅱb randomized trial[J]. Br J Dermatol, 2019, 180: 1030-1038. DOI: 10.1111/bjd.17455
|
[36] |
Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults[J]. Dermatol Ther (Heidelb), 2017, 7: 493-505. DOI: 10.1007/s13555-017-0201-6
|
[37] |
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic derma-titis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389: 2287-2303. DOI: 10.1016/S0140-6736(17)31191-1
|
[38] |
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial[J]. JAMA Dermatol, 2020, 156: 44-56. DOI: 10.1001/jamadermatol.2019.3336
|
[39] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53: 81-88. https://www.cnki.com.cn/Article/CJFDTOTAL-LPFZ202005016.htm
|
[40] |
Ruzicka T, Mihara R. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis[J]. N Engl J Med, 2017, 376: 2092-2093. DOI: 10.1056/NEJMc1704013
|
[41] |
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis[J]. JAKSTAT, 2013, 2: e24137.
|
[42] |
Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80: 913-921. e9. DOI: 10.1016/j.jaad.2018.01.018
|
[43] |
Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicen-tre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396: 255-266. DOI: 10.1016/S0140-6736(20)30732-7
|
[44] |
Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145: 877-884. DOI: 10.1016/j.jaci.2019.11.025
|
[45] |
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies[J]. J Am Acad Dermatol, 2021, 85: 863-872. DOI: 10.1016/j.jaad.2021.04.085
|
[46] |
Ciaravino V, Coronado D, Lanphear C, et al. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis[J]. J Dermatol Sci, 2017, 87: 116-122. DOI: 10.1016/j.jdermsci.2017.03.020
|
[47] |
Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019, 11: eaax2945. DOI: 10.1126/scitranslmed.aax2945
|
[48] |
黄世杰. 依托吉单抗治疗中重度特应性皮炎未能达到主终点[J]. 国际药学研究杂志, 2020, 47: 402. https://www.cnki.com.cn/Article/CJFDTOTAL-GWYZ202005014.htm
|
[49] |
Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial[J]. J Am Acad Dermatol, 2019, 80: 1013-1021. DOI: 10.1016/j.jaad.2018.11.059
|
[1] | WANG Jun, MENG Juan. Targeted Therapy for Rheumatoid Arthritis in the New Era[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 19-27. DOI: 10.12290/xhyxzz.2024-0842 |
[2] | YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 58-67. DOI: 10.12290/xhyxzz.2023-0391 |
[3] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
[4] | LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019 |
[5] | Hua-xia YANG, Feng-chun ZHANG. New Biologic Targets for Systemic Lupus Erythematosus: Hope and Challenge[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 241-246. DOI: 10.3969/j.issn.1674-9081.20200091 |
[6] | Cheng-mei HE, Feng-chun ZHANG. Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 130-134. DOI: 10.3969/j.issn.1674-9081.20190114 |
[7] | He-wen TANG, Meng YANG, Yu-xin JIANG. Molecular Contrast Agents for Photoacoustic Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 358-363. DOI: 10.3969/j.issn.1674-9081.2018.04.013 |
[8] | Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. DOI: 10.3969/j.issn.1674-9081.2017.05.018 |
[9] | Zhao-jing XUE, Le SHEN, Zhi-yao WANG, Yu-guang HUANG. Feasibility of Signal Transducers and Activators of Transcription 3 Inhibitor WP1066 as a Novel Target for Neuropathic Pain[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(2): 142-147. DOI: 10.3969/j.issn.1674-9081.2014.02.003 |
[10] | Liang ZHU, Jian LIU, Jing LEI, Hai-yan XU, Jie MENG, Yong-lan HE, Zheng-yu JIN, Hua-dan XUE. Development of a Peptide-based Cancer-specific Magnetic Resonance Contrast Agent Targeting CXCR4 and Validation of Its Effects in Three Cancer Cell Lines[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(3): 286-293. DOI: 10.3969/j.issn.1674-9081.2013.03.014 |